GC Pharma, a major Korean biopharmaceutical company, is facing a further delay in winning U.S. approval on its blood derivatives IVIS-SN as it recently received a second Complete Response Letter (CRL) notification from the U.S. FDA.The company completed the submission of supplementary data in March